# Adaptive Study of IL-2 Dose Frequency on Regulatory T Cells in Type 1 Diabetes

> **NCT02265809** · PHASE1,PHASE2 · COMPLETED · sponsor: **Cambridge University Hospitals NHS Foundation Trust** · enrollment: 41 (actual)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **DRUG:** Aldesleukin

## Key facts

- **NCT ID:** NCT02265809
- **Lead sponsor:** Cambridge University Hospitals NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-03
- **Primary completion:** 2016-05-26
- **Final completion:** 2016-05-26
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2018-08-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02265809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02265809, "Adaptive Study of IL-2 Dose Frequency on Regulatory T Cells in Type 1 Diabetes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02265809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*